Diagnostics have been taking off around health care, from fast risers like Illumina to tried-and-true companies like Thermo-Fisher. Don't miss out on this health boom.
An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharmaceutical company, and a rough week for two biotech standouts are this week's top stories.
How about a 50% gain in one week? That's the worst performance among these health-care high flyers.
The details behind Roche's deal with Pacific Biosciences of California.
Is Pacific Biosciences' new arrangement with Roche a good deal? Mr. Market gives PacBio's deal a big thumbs up.
Two important things you need to know about the future of Illumina.
The medical-technology company isn't well known, but investors have pushed Waters stock up toward all-time records.
With the potential for an epidemic at hand, we look at things from a glass-half-full perspective.
Let's see what the numbers say about Illumina (ILMN).
Thermo Fisher buys Life Technologies for $13.6 billion, but is it a good deal?